Denali Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026, generating $3.6 million in net product revenue from its first full quarter of commercial sales for AVLAYAH, an enzyme replacement therapy for Hunter syndrome. The company recorded a net loss of $127.6 million and reported total research and development expenses of $97.0 million alongside selling, general, and administrative costs of $36.3 million. In July 2026, Denali received $195 million in gross proceeds from the sale of a Priority Review Voucher associated with AVLAYAH, bringing pro forma cash, cash equivalents, and marketable securities to more than $1.1 billion. The company also announced that enrollment is complete for its Phase 1/2 study of DNL593 for frontotemporal dementia, with results now expected in 2027. Denali Therapeutics Inc. operates as a biotechnology company pioneering biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle platform.

Denali Therapeutics Inc. completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) on July 27, 2026, receiving gross proceeds of $195.0 million. The PRV was obtained in March 2026 following the U.S. FDA approval of AVLAYA (tividenofusp alfa) for the treatment of Hunter syndrome. The transaction was executed under an asset purchase agreement dated June 12, 2026. Denali Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development of treatments for rare and difficult-to-treat diseases.

Denali Therapeutics Inc. entered into an asset purchase agreement to sell its FDA-awarded Rare Pediatric Disease Priority Review Voucher (PRV) for $195 million in cash. The voucher was earned through the approval of AVLAYAHTM (tividenofusp alfa) for Hunter syndrome in March 2026. Denali Therapeutics Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.